This years’ Cost-effectiveness Award goes to Standard Treatment or Active Surveillance of Low-Risk Ductal Carcinoma In Situ in the LORD-trial from Antoni van Leeuwenhoek, Borstkanker Onderzoek Groep (BOOG) and BVN – Borstkankervereniging Nederland Congratulations!